CSL upbeat on new iron focus as it lifts lid on Vifor buy
smh.com.au
business
2022-10-17 01:43:42

CSL boss Paul Perreault has told investors there could be decades of growth on offer as the biotech giant expands its focus to treating patients with iron deficiency, heart failure and kidney disease through its $18.8 billion purchase of Swiss company Vifor.Perreault defended CSL's purchase of the business on Monday as management lifted the lid on the strategy and financial implications that will flow on from the purchase of the business, now called CSL Vifor.Analysts initially had a mixed response to the Vifor purchase, cautious about the big price tag paid.
